<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019, also known as COVID-19, is caused by a"/>
 <result pre="as COVID-19, is caused by a novel coronavirus named severe" exact="acute" post="respiratory syndrome coronavirus 2, or SARS-CoV-2. The infection has"/>
 <result pre="COVID-19, is caused by a novel coronavirus named severe acute" exact="respiratory" post="syndrome coronavirus 2, or SARS-CoV-2. The infection has now"/>
 <result pre="is caused by a novel coronavirus named severe acute respiratory" exact="syndrome" post="coronavirus 2, or SARS-CoV-2. The infection has now catapulted"/>
 <result pre="named severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. The" exact="infection" post="has now catapulted into a full-blown pandemic across the"/>
 <result pre="viruses have a zoonotic origin and can cause potentially lethal" exact="disease" post="in humans. Bats are the natural reservoir for a"/>
 <result pre="genetically related to other CoVs such as those causing severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndromeÂ (MERS),"/>
 <result pre="related to other CoVs such as those causing severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndromeÂ (MERS), which"/>
 <result pre="to other CoVs such as those causing severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndromeÂ (MERS), which cause"/>
 <result pre="those causing severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndromeÂ (MERS), which cause pneumonia and related diseases in"/>
 <result pre="syndrome (SARS) and Middle East respiratory syndromeÂ (MERS), which cause" exact="pneumonia" post="and related diseases in humans [4]. The novel CoV,"/>
 <result pre="and that the virus was transmitted to humans through an" exact="intermediate" post="host after accumulating a number of mutations. CoVs belong"/>
 <result pre="of viruses that are responsible for causing mild to severe" exact="respiratory" post="diseases in humans [6]. They contain external spike proteins"/>
 <result pre="mild to severe respiratory diseases in humans [6]. They contain" exact="external" post="spike proteins in their envelope (Fig.Â 1), which give"/>
 <result pre="hundred nanometres [3]. The spike glycoprotein (protein S) is the" exact="primary" post="antigenic component of the virus particle. Protein N is"/>
 <result pre="S) is the primary antigenic component of the virus particle." exact="Protein" post="N is the nucleocapsid protein, which associates with the"/>
 <result pre="can also be employed as a marker in assays detecting" exact="viral" post="antigens. Fig. 1 Schematic drawing of a coronavirus [7]"/>
 <result pre="of the first two of these genera are responsible for" exact="disease" post="in humans as well as other animals [2]. Before"/>
 <result pre="advent of SARS-CoV-2, there were six CoVs known to cause" exact="infections" post="in humans [1]. Î²-CoVs that cause mild to severe"/>
 <result pre="infections in humans [1]. Î²-CoVs that cause mild to severe" exact="respiratory" post="diseases in humans include the novel SARS-CoV-2, which is"/>
 <result pre="with a high concentration of chlorine [8]. Under favorable conditions," exact="infectious" post="virions are capable of persisting on surfaces for periods"/>
 <result pre="of persisting on surfaces for periods up to several days." exact="Diseases" post="caused by coronaviruses in humans CoVs are known to"/>
 <result pre="caused by coronaviruses in humans CoVs are known to cause" exact="disease" post="in humans but can be associated with disease in"/>
 <result pre="to cause disease in humans but can be associated with" exact="disease" post="in animals as well [8]. New human CoVs arise"/>
 <result pre="known to infect mammals such as bats can also cause" exact="infection" post="in humans, causing mild to severe respiratory ailments. The"/>
 <result pre="can also cause infection in humans, causing mild to severe" exact="respiratory" post="ailments. The epidemics of SARS-CoV and MERS-CoV in 2002â€&quot;2003"/>
 <result pre="and 2012, respectively, were caused by CoVs that caused severe" exact="respiratory" post="diseases in humans [3]. SARS-CoV-2, which is the seventh"/>
 <result pre="discovered to date, originated in the city of Wuhan, China." exact="Diseases" post="in humans that are caused by CoVs are described"/>
 <result pre="that are caused by CoVs are described in detail below:" exact="Benign" post="CoVs are the second most frequent causative agents of"/>
 <result pre="colds in humans, the first being rhinoviruses. The frequency of" exact="infection" post="tends to increase in the â€œautumnâ€� and winter, usually"/>
 <result pre="to increase in the â€œautumnâ€� and winter, usually causing mild" exact="respiratory" post="illness. Typical symptoms of the common cold include sore"/>
 <result pre="many others, which can be accompanied by fever [2]. Some" exact="infections" post="may escalate to serious diseases such as pneumonia, especially"/>
 <result pre="respectively, caused diseases with similar symptoms [8]. These viruses caused" exact="acute" post="respiratory infections with the sudden emergence of flu-like symptoms"/>
 <result pre="caused diseases with similar symptoms [8]. These viruses caused acute" exact="respiratory" post="infections with the sudden emergence of flu-like symptoms and"/>
 <result pre="diseases with similar symptoms [8]. These viruses caused acute respiratory" exact="infections" post="with the sudden emergence of flu-like symptoms and the"/>
 <result pre="far higher for MERS (about 30%) than SARS. The coronavirus" exact="disease" post="that first occurred in 2019 has been named COVID-19"/>
 <result pre="has been named COVID-19 [9]. The causative agent of this" exact="infection" post="is the novel SARS-CoV-2, which tends to replicate in"/>
 <result pre="is the novel SARS-CoV-2, which tends to replicate in the" exact="upper" post="region of the human respiratory system. However, the virus"/>
 <result pre="tends to replicate in the upper region of the human" exact="respiratory" post="system. However, the virus can also enter the lower"/>
 <result pre="human respiratory system. However, the virus can also enter the" exact="lower" post="respiratory tract and can cause lesions despite the patient"/>
 <result pre="respiratory system. However, the virus can also enter the lower" exact="respiratory" post="tract and can cause lesions despite the patient remaining"/>
 <result pre="the individual. COVID-19 and its epidemiology SARS-CoV-2 is a highly" exact="infectious" post="and rapidly spreading CoV that originated in December 2019"/>
 <result pre="countries on all continents except â€œAntarcticaâ€�. The characteristics of the" exact="infection" post="and transmission are given below: In the early days"/>
 <result pre="[2]. The time on average for its exponential growth (and" exact="infection" post="of other individuals) was observed to be about 7Â"/>
 <result pre="be approximately 5 and 12Â days from the beginning of" exact="infection" post="to their first treatment and hospital care, respectively, and"/>
 <result pre="days, respectively [1]. The time from the manifestation of the" exact="disease" post="to its diagnosis in critically ill patients who eventually"/>
 <result pre="movements of infected people [6]. Channels of COVID-19 spread SARS-CoV-2" exact="infection" post="occurs through the mucosal membrane of the upper respiratory"/>
 <result pre="spread SARS-CoV-2 infection occurs through the mucosal membrane of the" exact="upper" post="respiratory tract [9]. Recent research has suggested two possible"/>
 <result pre="SARS-CoV-2 infection occurs through the mucosal membrane of the upper" exact="respiratory" post="tract [9]. Recent research has suggested two possible modes"/>
 <result pre="transmission. The virus can spread by through direct transmission via" exact="respiratory" post="droplets or by indirect transmission via surfaces and materials"/>
 <result pre="or more were observed to be critically affected by the" exact="disease" post="(30â€&quot;40%), with elevated fatality rates (approximately 5â€&quot;10%) for patients"/>
 <result pre="the females, with the majority of the infected patients exhibiting" exact="benign" post="or conventional symptoms (approximately 80%). Features of COVID-19 The"/>
 <result pre="has been characterized by the typical developmental stages of the" exact="disease" post="[10]. The initial stage of infection is usually characterized"/>
 <result pre="developmental stages of the disease [10]. The initial stage of" exact="infection" post="is usually characterized by fever, although many patients exhibit"/>
 <result pre="breathing, with the condition of the patient rapidly deteriorating to" exact="respiratory" post="failure in some critical cases [1]. However, in the"/>
 <result pre="of the cases, the prognosis is good, leading to a" exact="complete" post="recovery in patients with milder illness. Initial screening of"/>
 <result pre="screening of the lungs of infected patients tends to reveal" exact="pulmonary" post="development and change in the interstices, along with various"/>
 <result pre="along with various minute patches [10]. A characteristic feature of" exact="respiratory" post="failure known as â€œwhite lungâ€� is evident in the"/>
 <result pre="blood cells is characteristic of the initial stage of the" exact="infection" post="[10]. In some studies, an elevation in the levels"/>
 <result pre="some studies, an elevation in the levels of hepatic and" exact="muscle" post="enzymes and myoglobin has been reported, whereas in other"/>
 <result pre="screening of antibodies in infected individuals at the onset of" exact="disease" post="and again after fourteen days can be helpful in"/>
 <result pre="and biochemical parameters should be examined regularly, along with the" exact="chest" post="imaging and determination of blood oxygen levels [3]. If"/>
 <result pre="levels are observed to fluctuate, the patient may be given" exact="external" post="oxygen. Gas ventilators and nasal oxygen may be helpful"/>
 <result pre="nasal oxygen may be helpful for patients suffering from severe" exact="respiratory" post="distress. To date, no approved antiviral medicine has been"/>
 <result pre="treatment of the disease. However, patients should be examined for" exact="bacterial infections" post="and given antibacterial drugs in cases where there is"/>
 <result pre="of the disease. However, patients should be examined for bacterial" exact="infections" post="and given antibacterial drugs in cases where there is"/>
 <result pre="antibacterial drugs in cases where there is a risk of" exact="bacterial infection" post="[10]. Traditional Chinese medicine (TCM) should be used in"/>
 <result pre="drugs in cases where there is a risk of bacterial" exact="infection" post="[10]. Traditional Chinese medicine (TCM) should be used in"/>
 <result pre="be used in combination with conventional medicines after determining the" exact="infection" post="symptoms through the conventional method of diagnosis. XueBiJing, Huo"/>
 <result pre="for vaccine development was recently undertaken by the Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI), involving several countries [12]. In this"/>
 <result pre="remdesivir as an anti-COVID-19 treatment for COVID-19 patients suffering from" exact="pneumonia" post="[11]. Fig. 2 Drug discovery cycle [15] Rationalization of"/>
 <result pre="available on the medicinal market for the management of other" exact="infections" post="or have been formulated for recent clinical trials were"/>
 <result pre="including those caused by canine coronavirus, feline coronavirus, and contagious" exact="bronchitis" post="virusÂ in birds [11]. Previously, attempts were made to"/>
 <result pre="research efforts toward developing vaccines [33, 34]. Several organizations published" exact="viral" post="genome sequences to promote the development of safe and"/>
 <result pre="mRNA-1273 was registered by the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) in February 2020 to be tested in"/>
 <result pre="was registered by the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) in February 2020 to be tested in Seattle,"/>
 <result pre="study. Its mode of action is to bind to the" exact="viral" post="RNA polymerase in its active state, where its primary"/>
 <result pre="the viral RNA polymerase in its active state, where its" exact="primary" post="effect is to cause RNA chain termination. It is"/>
 <result pre="SARS-CoV-2, with suitable EC50 values. Because it is specific for" exact="viral" post="enzymes, it is less likely than some other drugs"/>
 <result pre="index values were obtained for this drug in a human" exact="respiratory" post="cell model, according to Sheahan et al. [81]. It"/>
 <result pre="been investigated in mice, which demonstrated a decrease in the" exact="viral" post="load in the lungs, in body weight loss, and"/>
 <result pre="overall lung destruction, which suggested that the drug can inhibit" exact="viral" post="replication in the initial stages of infection. However, it"/>
 <result pre="stages of infection. However, it was not effective when the" exact="viral" post="load was high [80]. The results of that study"/>
 <result pre="effective in reducing virus replication and the eventual onset of" exact="disease" post="caused by SARS-CoV-1 [80, 81]. It is important to"/>
 <result pre="the discontinuation of the drug for the treatment of this" exact="disease" post="[85]. The first case of treatment of a patient"/>
 <result pre="corroborated the safety data from cases of treatment of other" exact="viral" post="infections with this drug [87, 88]. Nonetheless, it is"/>
 <result pre="the safety data from cases of treatment of other viral" exact="infections" post="with this drug [87, 88]. Nonetheless, it is important"/>
 <result pre="meet these criteria, suffer from organ failure, have renal and" exact="hepatic disease," post="or receive dialysis, they are exempted from compassionate use."/>
 <result pre="hydroxychloroquine Chloroquine is an anti-parasitic drug that is used against" exact="malaria" post="due to its inflammation-reducing properties and its ability to"/>
 <result pre="not sufficient for its widespread use, as supply-related problems and" exact="cardiovascular" post="toxicity have restricted their use in countries like the"/>
 <result pre="use of which has been associated with a rise in" exact="rheumatic" post="disorders. The current data regarding the activity of hydroxychloroquine"/>
 <result pre="a pharmacology-based pharmacokinetic (PBPK) model to examine their activity in" exact="respiratory" post="organs, the findings were the opposite of the previous"/>
 <result pre="chloroquine. The second dosage gave similar results, suggesting that a" exact="lower" post="dosage of hydroxychloroquine was also effective [65]. However, it"/>
 <result pre="regimens of therapy [92]. It is advised to wait for" exact="complete" post="validation and more published data before the administration of"/>
 <result pre="antibacterial drug azithromycin, which was given in patients to prevent" exact="bacterial infection" post="in COVID-19 cases, resulted in a stronger reduction in"/>
 <result pre="drug azithromycin, which was given in patients to prevent bacterial" exact="infection" post="in COVID-19 cases, resulted in a stronger reduction in"/>
 <result pre="in COVID-19 cases, resulted in a stronger reduction in the" exact="viral" post="load than the use of hydroxychloroquine alone. This finding,"/>
 <result pre="consideration. Clinical data were not adequate, although the reduction in" exact="viral" post="load was noteworthy. The study included 26 patients receiving"/>
 <result pre="Lastly, the patients in the study had a much higher" exact="viral" post="titer, as demonstrated by CT values, than other patients"/>
 <result pre="with corticosteroids, after which a considerable decrease in the â€œacute" exact="respiratory" post="distress syndromeâ€� (ARDS) and fatality rate was observed. This"/>
 <result pre="on more than 70 lopinavir/ritonavir-treated patients who exhibited an overall" exact="lower" post="fatality rate than patients who did not receive the"/>
 <result pre="condition of infected patients and an overall reduction in the" exact="viral" post="titer after lopinavir/ritonavir treatment. However, the efficacy of this"/>
 <result pre="results among studies, variation in the degree of severity of" exact="disease" post="in the subjects, and the absence of any standard"/>
 <result pre="degree of severity of disease in the subjects, and the" exact="absence of" post="any standard of treatment [103â€&quot;106]. Furthermore, the administration of"/>
 <result pre="combination therapy was compared to twice-a-day and standardized treatment of" exact="pneumonia" post="in COVID-19 patients [47]. The initial outcome evaluated was"/>
 <result pre="based on fatality rates, time until discharge from the hospital," exact="viral" post="load, and the amount of virus in pharyngeal swabs."/>
 <result pre="difference was found with respect to the decrease in the" exact="viral" post="load. The current data on lopinavir/ritonavir provide little information"/>
 <result pre="inadequate activity in animal models for the treatment of MERS-CoV" exact="infection" post="is also not encouraging. It is also noteworthy that,"/>
 <result pre="randomized trial conducted recently, the time from the start of" exact="infection" post="to the commencement of the drug regimen was 13Â"/>
 <result pre="replication [111]. It is under evaluation for its potency against" exact="respiratory" post="viruses. In one study, oral administration ( 112]. This"/>
 <result pre="which is released by human macrophages and monocytes during cytokine-release" exact="syndrome" post="(CRS). Since its approval by the FDA in 2010,"/>
 <result pre="has been used as a therapeutic agent in patients with" exact="rheumatoid arthritis" post="as a corticosteroid-sparing agent in chimeric antigen receptor T-cell"/>
 <result pre="been used as a therapeutic agent in patients with rheumatoid" exact="arthritis" post="as a corticosteroid-sparing agent in chimeric antigen receptor T-cell"/>
 <result pre="its severity [115]. The administration of tocilizumab in arteritis or" exact="arthritis" post="patients results in neutropenia or thrombocytopenia, which makes patients"/>
 <result pre="administration of tocilizumab in arteritis or arthritis patients results in" exact="neutropenia" post="or thrombocytopenia, which makes patients more prone to secondary"/>
 <result pre="in neutropenia or thrombocytopenia, which makes patients more prone to" exact="secondary" post="bacterial infections due to release of IL-6. In a"/>
 <result pre="neutropenia or thrombocytopenia, which makes patients more prone to secondary" exact="bacterial infections" post="due to release of IL-6. In a case study,"/>
 <result pre="or thrombocytopenia, which makes patients more prone to secondary bacterial" exact="infections" post="due to release of IL-6. In a case study,"/>
 <result pre="infections due to release of IL-6. In a case study," exact="adult" post="patients with refractory acute B-cell lymphoblastic leukemia and with"/>
 <result pre="of IL-6. In a case study, adult patients with refractory" exact="acute" post="B-cell lymphoblastic leukemia and with grade 3 or higher"/>
 <result pre="In a case study, adult patients with refractory acute B-cell" exact="lymphoblastic leukemia" post="and with grade 3 or higher CRS were found"/>
 <result pre="a case study, adult patients with refractory acute B-cell lymphoblastic" exact="leukemia" post="and with grade 3 or higher CRS were found"/>
 <result pre="grade 3 or higher CRS were found to suffer from" exact="secondary" post="bacterial infections. In those patients, it was hard to"/>
 <result pre="3 or higher CRS were found to suffer from secondary" exact="bacterial infections." post="In those patients, it was hard to identify the"/>
 <result pre="to identify the triggering factor (tocilizumab or corticosteroid) for these" exact="bacterial infections" post="[116]. However, no side effects of tocilizumab were reported"/>
 <result pre="identify the triggering factor (tocilizumab or corticosteroid) for these bacterial" exact="infections" post="[116]. However, no side effects of tocilizumab were reported"/>
 <result pre="repeat a dose in 12Â h (not to exceed a" exact="total" post="dose of 800Â mg). Chinese scientists are working on"/>
 <result pre="as there is a need to study their role in" exact="secondary" post="infections and other adverse side effects. They have been"/>
 <result pre="there is a need to study their role in secondary" exact="infections" post="and other adverse side effects. They have been administered"/>
 <result pre="They have been administered in cases of MERS-CoV- and SARS-CoV-1-related" exact="pneumonia" post="as a supplementary therapy, but their exact role is"/>
 <result pre="corticosteroids immediately enhances fever and leads to a risk of" exact="secondary" post="infections by bacteria, and thus poor outcomes, and for"/>
 <result pre="immediately enhances fever and leads to a risk of secondary" exact="infections" post="by bacteria, and thus poor outcomes, and for this"/>
 <result pre="care during their intensive care period. The stage of the" exact="disease" post="must be kept in mind when choosing a dosage"/>
 <result pre="Peopleâ€™s Republic of China, where the authors state, â€œBased on" exact="respiratory" post="distress and chest imaging, may consider glucocorticoid that is"/>
 <result pre="China, where the authors state, â€œBased on respiratory distress and" exact="chest" post="imaging, may consider glucocorticoid that is equivalent to methylprednisolone"/>
 <result pre="of SARS-CoV-2.â€� [102]. A recent consensus statement from the Chinese" exact="Thoracic" post="Society recommends a lower dose,â€‰â‰¤â€‰0.5â€&quot;1Â mg/kg per day methylprednisolone"/>
 <result pre="recent consensus statement from the Chinese Thoracic Society recommends a" exact="lower" post="dose,â€‰â‰¤â€‰0.5â€&quot;1Â mg/kg per day methylprednisolone forâ€‰â‰¤â€‰7Â days in select"/>
 <result pre="or without interferon Ribavirin was approved in the 1980s for" exact="viral" post="hemorrhagic fever, respiratory syncytial virus infection, and hepatitis C,"/>
 <result pre="Ribavirin was approved in the 1980s for viral hemorrhagic fever," exact="respiratory" post="syncytial virus infection, and hepatitis C, together with interferon."/>
 <result pre="approved in the 1980s for viral hemorrhagic fever, respiratory syncytial" exact="virus infection," post="and hepatitis C, together with interferon. It is a"/>
 <result pre="1980s for viral hemorrhagic fever, respiratory syncytial virus infection, and" exact="hepatitis C," post="together with interferon. It is a guanosine analogue known"/>
 <result pre="one of the â€œstandard treatmentâ€� options for COVID-19. Due to" exact="limited" post="data and a lack of experimental trials, it is"/>
 <result pre="with antibiotics. At that time, the causative agent of the" exact="disease" post="was not known, and an attempt was made to"/>
 <result pre="of different pharmacological agents against COVID-19 at various levels of" exact="infection" post="and disease development. Table 1 Pharmacological agents being investigated"/>
 <result pre="pharmacological agents against COVID-19 at various levels of infection and" exact="disease" post="development. Table 1 Pharmacological agents being investigated against COVID-19"/>
 <result pre="yet Umifenovir Antiviral/used against influenza Inhibits fusion China Baricitinib Treats" exact="rheumatoid arthritis" post="A Janus kinase family (JAK) enzyme inhibitor Not registered"/>
 <result pre="Umifenovir Antiviral/used against influenza Inhibits fusion China Baricitinib Treats rheumatoid" exact="arthritis" post="A Janus kinase family (JAK) enzyme inhibitor Not registered"/>
 <result pre="inhibitor Not registered yet Bevacizumab Recombinant humanized monoclonal antibody/used against" exact="cancer" post="Prevents vascular endothelial growth factor associated with endothelial receptors"/>
 <result pre="registered yet Bevacizumab Recombinant humanized monoclonal antibody/used against cancer Prevents" exact="vascular" post="endothelial growth factor associated with endothelial receptors Flt-1 and"/>
 <result pre="mimetic USA Convalescent plasma From patients who have recovered from" exact="viral" post="infections Via production of antibodies against a disease agent"/>
 <result pre="USA Convalescent plasma From patients who have recovered from viral" exact="infections" post="Via production of antibodies against a disease agent Not"/>
 <result pre="recovered from viral infections Via production of antibodies against a" exact="disease" post="agent Not registered yet Darunavir/cobicistat Anti-retroviral HIV-1 protease inhibitor"/>
 <result pre="protein of MERS-CoV USA Sarilumab Human monoclonal antibody/ used against" exact="rheumatoid arthritis" post="IL-6 receptor antagonist USA Sofosbuvir Antiviral A nucleotide analog"/>
 <result pre="of MERS-CoV USA Sarilumab Human monoclonal antibody/ used against rheumatoid" exact="arthritis" post="IL-6 receptor antagonist USA Sofosbuvir Antiviral A nucleotide analog"/>
 <result pre="receptor antagonist USA Sofosbuvir Antiviral A nucleotide analog inhibitor of" exact="hepatitis C" post="virus Not registered yet TZLS-501 Human monoclonal antibody Anti-IL6R"/>
 <result pre="of various pharmacological agents against COVID-19 at various levels of" exact="infection" post="and disease progression Nitric oxide therapy against COVID-19 Nitric"/>
 <result pre="pharmacological agents against COVID-19 at various levels of infection and" exact="disease" post="progression Nitric oxide therapy against COVID-19 Nitric oxide gas"/>
 <result pre="side of the heart, which is under direct pressure during" exact="cardiac arrest." post="It also has anti-COVID-19 features that were studied previously"/>
 <result pre="achieved by providing the recipient with antibodies against a specific" exact="disease" post="and is regarded as a safe means of providing"/>
 <result pre="as a safe means of providing immediate immunity against any" exact="disease" post="in healthy humans. Unsurprisingly, its history dates back to"/>
 <result pre="it was often the only method used to treat an" exact="infectious disease," post="before the advent of antibiotics in the 20th century"/>
 <result pre="that immune serum can be used for treatment of CoV" exact="infections" post="[133]. Similarly, passive antibody therapy would work against SARS-CoV-2"/>
 <result pre="likely to be most effective in the initial stages of" exact="infection" post="when the viral load is lower, allowing neutralization by"/>
 <result pre="most effective in the initial stages of infection when the" exact="viral" post="load is lower, allowing neutralization by antibodies to occur"/>
 <result pre="the early stages of infection. Previously, passive antibody therapy against" exact="pneumococcal pneumonia" post="was observed to be most efficacious when it was"/>
 <result pre="early stages of infection. Previously, passive antibody therapy against pneumococcal" exact="pneumonia" post="was observed to be most efficacious when it was"/>
 <result pre="Use of convalescent sera to treat patients suffering from COVID-19." exact="Blood" post="is drawn from a patient who has recently recovered"/>
 <result pre="still unknown, it is known to prevent the occurrence of" exact="disease" post="Historical precedents Serum antibodies have long been used in"/>
 <result pre="the treatment of many diseases caused by viruses, such as" exact="poliomyelitis" post="[138], measles [139, 140], mumps [141], and influenza [142]."/>
 <result pre="of many diseases caused by viruses, such as poliomyelitis [138]," exact="measles" post="[139, 140], mumps [141], and influenza [142]. A meta-analysis"/>
 <result pre="caused by viruses, such as poliomyelitis [138], measles [139, 140]," exact="mumps" post="[141], and influenza [142]. A meta-analysis showed that the"/>
 <result pre="type of treatment was observed to be dependent on the" exact="viral" post="pathogen, it has been employed in numerous viral outbreaks"/>
 <result pre="on the viral pathogen, it has been employed in numerous" exact="viral" post="outbreaks that claimed the lives of millions of people."/>
 <result pre="of serum antibodies has increased in the wake of recent" exact="viral" post="outbreaks. They were employed in the treatment of patients"/>
 <result pre="influenza pandemic, where they led to a decrease in the" exact="respiratory" post="distress and fatality rates in critically ill patients [144]."/>
 <result pre="Ebola outbreak [145]. Furthermore, evidence from studies conducted during various" exact="viral" post="outbreaks worldwide suggests that treatment with sera from convalescent"/>
 <result pre="two decades have established CoVs as dangerous pathogens that can" exact="disease" post="in humans. The SARS epidemic was subdued with strict"/>
 <result pre="the Middle Eastern countries, followed by a second wave of" exact="infection" post="in South Korea. In both of these viral outbreaks,"/>
 <result pre="wave of infection in South Korea. In both of these" exact="viral" post="outbreaks, high mortality and contagion of disease were observed,"/>
 <result pre="both of these viral outbreaks, high mortality and contagion of" exact="disease" post="were observed, which made the spread hard to curb."/>
 <result pre="patients. Upon administration, the individuals treated on day 14 after" exact="disease" post="onset, as well as those who tested positive by"/>
 <result pre="early treatment [150]. Another study highlighted the decrease in the" exact="viral" post="titer, thus enabling the survival of infected patients after"/>
 <result pre="can also contribute to immunity to and recuperation from many" exact="viral" post="diseases [154â€&quot;156]. In the case of SARS-CoV-2, there were"/>
 <result pre="to infected individuals, and they are used for treatment of" exact="respiratory" post="syncytial virus (RSV) disease in susceptible children. Previously, for"/>
 <result pre="they are used for treatment of respiratory syncytial virus (RSV)" exact="disease" post="in susceptible children. Previously, for both prevention and treatment,"/>
 <result pre="to be useful for prevention than for rigorous treatment of" exact="infection" post="[142]. A major risk of this therapy is the"/>
 <result pre="blood screening practices in which donated blood is screened for" exact="infectious" post="agents and reactions with the blood of serum recipients."/>
 <result pre="serum recipients. Nonetheless, the administration of sera in patients with" exact="pulmonary" post="disease carries the risk of transfusion-related acute lung injury"/>
 <result pre="recipients. Nonetheless, the administration of sera in patients with pulmonary" exact="disease" post="carries the risk of transfusion-related acute lung injury (TRALI)"/>
 <result pre="in patients with pulmonary disease carries the risk of transfusion-related" exact="acute" post="lung injury (TRALI) [158], which should be contemplated in"/>
 <result pre="therapy is antibody-dependent enhancement (ADE) of infection. An escalation of" exact="infection" post="can occur due to various antibodies present in the"/>
 <result pre="occurrence that can take place in the case of many" exact="viral" post="diseases. This threat is of particular concern in the"/>
 <result pre="antibodies against one type of CoV can intensify the resulting" exact="infection" post="with another CoV. Still, the intensity of the threat"/>
 <result pre="intensification of disease. The vulnerability of recovered patients to a" exact="secondary" post="infection, enabled by the suppression of the host immune"/>
 <result pre="assumed that the patients who have recuperated successfully from SARS-CoV-2" exact="infection" post="can be safely requested to donate their blood to"/>
 <result pre="the donated blood should also be critically screened for any" exact="infectious" post="agents and blood type. It is also imperative to"/>
 <result pre="studies have reported the amount of convalescent sera used against" exact="measles" post="to be in the range of 0â€&quot;50Â cc. In"/>
 <result pre="prevention or subsequent treatment of infection. Therefore, prophylaxis against of" exact="infection" post="by providing small doses might be efficacious, whereas larger"/>
 <result pre="larger doses may be needed to treat disease, as the" exact="viral" post="load at the onset of the disease is much"/>
 <result pre="disease, as the viral load at the onset of the" exact="disease" post="is much lower than during the peak of the"/>
 <result pre="viral load at the onset of the disease is much" exact="lower" post="than during the peak of the disease. The serum"/>
 <result pre="be employed in the treatment of patients displaying onset of" exact="disease" post="[164, 165]. Many healthcare staff and paramedics who have"/>
 <result pre="been advised to quarantine or self-isolate, which greatly increases the" exact="disease" post="burden on the remaining health care officials. This burden"/>
 <result pre="production and use of this therapy against the COVID-19 pandemic." exact="Mesenchymal" post="stem cell technology Clinicians are aiming to save the"/>
 <result pre="the lives of COVID-19 patients by controlling the rate of" exact="infection" post="and death [166]. Generally, it has been observed that"/>
 <result pre="aspect is not taken seriously, i.e., the pathogenesis of SARS-CoV-2." exact="Infection" post="causes cytokines (IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A"/>
 <result pre="disturb the exchange of gases in the lungs, leading to" exact="acute" post="respiratory distress, cardiac arrest, and secondary infections. According to"/>
 <result pre="the exchange of gases in the lungs, leading to acute" exact="respiratory" post="distress, cardiac arrest, and secondary infections. According to a"/>
 <result pre="of gases in the lungs, leading to acute respiratory distress," exact="cardiac arrest," post="and secondary infections. According to a recent study, patients"/>
 <result pre="the lungs, leading to acute respiratory distress, cardiac arrest, and" exact="secondary" post="infections. According to a recent study, patients shed the"/>
 <result pre="14% are severely ill, and 6% are in critical condition." exact="Mesenchymal" post="stem cells Chinese researchers have observed that stem cell"/>
 <result pre="They concluded that natural mechanisms could be used to treat" exact="acute" post="inflammatory pneumonia. For example, in one case, liver fibrosis"/>
 <result pre="to treat acute inflammatory pneumonia. For example, in one case," exact="liver fibrosis" post="was treated well with â€œhuman umbilical cord mesenchymal stem"/>
 <result pre="COVID-19. Synthetic stem cells â€&quot; â€œLIFNanoâ€� In the case of" exact="pneumonia" post="caused by viruses, â€œleukemia inhibitory factorâ€� (LIF), is a"/>
 <result pre="model for â€œmultiple sclerosisâ€� (MS), LIFNano was effective in â€œexperimental" exact="autoimmune" post="encephalomyelitisâ€� (EAE) for treating paralysis within 96Â h (Fig.Â"/>
 <result pre="The effect of LIF on responses against the pathogenesis of" exact="infection" post="(adapted from Quinton et al. [170]). Earlier studies highlighted"/>
 <result pre="its over-regulation [174], which can lead to the inhibition of" exact="pulmonary" post="inflammation. This experiment demonstrates the protective role of LIF"/>
 <result pre="of LIF in the case of lung trauma. Lungs were" exact="acquired" post="from experimental mice one day after the introduction of"/>
 <result pre="newly isolated lungs with stained lung parts. Red circles indicate" exact="infection" post="in the lobes of lungs. (B) Ratios of wet:dry"/>
 <result pre="(I-UK BMC) entitled â€œCell-free regenerative medicine: Nano-Engineered â€œLIFNanoâ€� to treat" exact="Multiple" post="Sclerosisâ€� Project number: 102847). Fast recovery of motor function"/>
 <result pre="deaths can be prevented by applying prophylactic measures in the" exact="absence of" post="typical treatment. Strict implementation of control regimes is essential"/>
 <result pre="implement effective and thorough protection initiatives for people vulnerable to" exact="viral infection." post="Although extensive research is being conducted to develop a"/>
 <result pre="major part of the ongoing research towards the treatment of" exact="pneumonia" post="in patients, which is often fatal. The astounding data"/>
 <result pre="pathway for the treatment of disease. In the case of" exact="pneumonia" post="caused by COVID-19, the balance between the antiviral response"/>
 <result pre="before end of April [https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months. Retrieved 10 Apr 2020 25.Severe" exact="acute" post="respiratory syndrome (SARS). https://www.cdc.gov/sars/. Retrieved 10 Apr 2020 26.PrompetcharaEKetloyCPalagaTImmune"/>
 <result pre="end of April [https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months. Retrieved 10 Apr 2020 25.Severe acute" exact="respiratory" post="syndrome (SARS). https://www.cdc.gov/sars/. Retrieved 10 Apr 2020 26.PrompetcharaEKetloyCPalagaTImmune responses"/>
 <result pre="of April [https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months. Retrieved 10 Apr 2020 25.Severe acute respiratory" exact="syndrome" post="(SARS). https://www.cdc.gov/sars/. Retrieved 10 Apr 2020 26.PrompetcharaEKetloyCPalagaTImmune responses in"/>
 <result pre="SARS and MERS epidemicAsian Pac J Allergy Immunol20203811932105090 27.Middle East" exact="Respiratory" post="Syndrome (MERS). https://www.cdc.gov/coronavirus/mers/index.html. Retrieved 12 Apr 2020 28.GaoWTaminASoloffAD'AiutoLNwanegboERobbinsPDBelliniWJBarratt-BoyesSGambottoAEffects of"/>
 <result pre="and MERS epidemicAsian Pac J Allergy Immunol20203811932105090 27.Middle East Respiratory" exact="Syndrome" post="(MERS). https://www.cdc.gov/coronavirus/mers/index.html. Retrieved 12 Apr 2020 28.GaoWTaminASoloffAD'AiutoLNwanegboERobbinsPDBelliniWJBarratt-BoyesSGambottoAEffects of a"/>
 <result pre="coronavirus vaccine in monkeysLancet200336293991895189614667748 29.KimEOkadaKKennistonTRajVSAlHajriMMFaragEAAlHajriFOsterhausADHaagmansBLGambottoAImmunogenicity of an adenoviral-based middle east" exact="respiratory" post="syndrome coronavirus vaccine in BALB/c miceVaccine201432455975598225192975 30.JiangSLuLDuLDevelopment of SARS"/>
 <result pre="vaccine in monkeysLancet200336293991895189614667748 29.KimEOkadaKKennistonTRajVSAlHajriMMFaragEAAlHajriFOsterhausADHaagmansBLGambottoAImmunogenicity of an adenoviral-based middle east respiratory" exact="syndrome" post="coronavirus vaccine in BALB/c miceVaccine201432455975598225192975 30.JiangSLuLDuLDevelopment of SARS vaccines"/>
 <result pre="SARS vaccines and therapeutics is still neededFuture Virol20138101 31.SARS (severe" exact="acute" post="respiratory syndrome). https://www.nhs.uk/conditions/sars/. Retrieved 12 Apr 2020 32.YongCYOngHKYeapSKHoKLTanWSRecent advances"/>
 <result pre="vaccines and therapeutics is still neededFuture Virol20138101 31.SARS (severe acute" exact="respiratory" post="syndrome). https://www.nhs.uk/conditions/sars/. Retrieved 12 Apr 2020 32.YongCYOngHKYeapSKHoKLTanWSRecent advances in"/>
 <result pre="2020 32.YongCYOngHKYeapSKHoKLTanWSRecent advances in the vaccine development against middle east" exact="respiratory" post="syndrome-coronavirusFront Microbiol201910178131428074 33.FauciASLaneHCRedieldRRCovid-19â€&quot;navigating the unchartedN Engl J Med20203821268126910.1056/NEJMe200238732109011 34.GatesBResponding"/>
 <result pre="Apr 2020 56.ZhangLLiuYPotential interventions for novel coronavirus in China: a" exact="systemic" post="reviewJ Med Virol202092547949032052466 57.Coronavirus: Japanese anti-viral drug effective in"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends 14(1):72â€&quot;73 (PubMed PMID: 32074550."/>
 <result pre="of Novel Coronavirus PneumoniaExpert Consens Chloroquine Phosphate Treat Novel Coronavirus" exact="Pneumonia" post="[in Chinese]202020201010011939 63.Physicians work out treatment guidelines for coronavirus."/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 66.Van Norman"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 66.Van Norman GA"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 66.Van Norman GA (2019)"/>
 <result pre="tissues. https://www.eurekalert.org/pub_releases/2020-04/uobc-tdc040220.php. Retrieved 12 Apr 2020 75.MonteilVKwonHPradoPHagelkrÃ¼ysAWimmerRAStahlMet al.Inhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell20201814905913.e732333836"/>
 <result pre="design of improved Î±-ketoamide inhibitorsScience2020368648940941232198291 77.DongLHuSGaoJDiscovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov Ther2020141586032147628 78.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine effectively inhibit"/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem AC120:013056 80.SheahanTSimsALeistSSchÃ¤ferAWonJBrownAMontgomerySHoggABabusisDClarkeMComparative therapeutic efficacy"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem AC120:013056 80.SheahanTSimsALeistSSchÃ¤ferAWonJBrownAMontgomerySHoggABabusisDClarkeMComparative therapeutic efficacy of"/>
 <result pre="GS-5734 inhibits both epidemic and zoonotic coronavirusesSci Transl Med20179396EAAL365328659436 82.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRCoronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleaseMBio201892e00221e121829511076 83.SiegelDHuiHCDoerfflerEClarkeMOChunKZhangLet al.Discovery and synthesis"/>
 <result pre="85.MulanguSDoddLEDaveyRTJrTshiani MbayaOProschanMMukadiDLusakibanza ManzoMNzoloDTshomba OlomaAIbandaAA randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med2019381242293230331774950 86.HolshueMLDeBoltCLindquistSLofyKWiesmanJBruceHet al.First case of 2019"/>
 <result pre="Ebola virus diseaseJ Infect Dis2017215217117428073857 89.First 12 patients with coronavirus" exact="disease" post="2019 (COVID-19) in the United States. https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf. Retrieved 14"/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 98.AspirozELBuelgaDSFigueroaSCGaleraRMLPascuetERHurlÃ©"/>
 <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 98.AspirozELBuelgaDSFigueroaSCGaleraRMLPascuetERHurlÃ© AD-G,"/>
 <result pre="(2015) Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
 <result pre="J Infect Dis 212(12):1904â€&quot;1913 100.ArabiYMAsiriAYAssiriAMJokhdarHAAAlothmanABalkhyHHAlJohaniSAl HarbiSKojanSAl JeraisyMTreatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE"/>
 <result pre="Infect Dis 212(12):1904â€&quot;1913 100.ArabiYMAsiriAYAssiriAMJokhdarHAAAlothmanABalkhyHHAlJohaniSAl HarbiSKojanSAl JeraisyMTreatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="recursive two-stage group sequential randomized controlled trialTrials20202111831898511 101.QueTWongVYuenKTreatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="two-stage group sequential randomized controlled trialTrials20202111831898511 101.QueTWongVYuenKTreatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="group sequential randomized controlled trialTrials20202111831898511 101.QueTWongVYuenKTreatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="Kong Med J20039639940614660806 102.The diagnosis and treatment guide of COVID-19" exact="pneumonia" post="caused by new coronavirus infection, 7th edn. https://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.html. Accessed"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RTPCRJ Korean Med Sci2020356E7932056407 105.HanWQuanBGuoYZhangJLuYFengGWuQFangFChengLJiaoNLiXChenQThe course"/>
 <result pre="clinical diagnosis and treatment of a case infected with coronavirus" exact="disease" post="2019J Med Virol202092546146332073161 106.WangZChenXLuYChenFZhangWClinical characteristics and therapeutic procedure for"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends2020141646832037389 107.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYet"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231110611069 108.ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYEpidemiological and clinical characteristics of 99"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751332007143 109.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course"/>
 <result pre="studyLancet20203951022350751332007143 109.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirusJ Infect Public Health20169322723027095301 112.HaffizullaJHartmanAHoppersMResnickHSamudralaSGinocchioCBardinMRossignolJEffect of nitazoxanide in"/>
 <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirusJ Infect Public Health20169322723027095301 112.HaffizullaJHartmanAHoppersMResnickHSamudralaSGinocchioCBardinMRossignolJEffect of nitazoxanide in adults"/>
 <result pre="Public Health20169322723027095301 112.HaffizullaJHartmanAHoppersMResnickHSamudralaSGinocchioCBardinMRossignolJEffect of nitazoxanide in adults and adolescents with" exact="acute" post="uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trialLancet"/>
 <result pre="addition to standard of care for the treatment of severe" exact="acute" post="respiratory illnessClin Infect Dis201969111903191130753384 114.KotchCBarrettDTeacheyDTTocilizumab for the treatment of"/>
 <result pre="to standard of care for the treatment of severe acute" exact="respiratory" post="illnessClin Infect Dis201969111903191130753384 114.KotchCBarrettDTeacheyDTTocilizumab for the treatment of chimeric"/>
 <result pre="syndromeExpert Rev Clin Immunol201915881382231219357 115.LeeDWSantomassoBDLockeFLGhobadiATurtleCJBrudnoJNMausMVParkJHMeadEPavleticSASTCT consensus grading for cytokine release" exact="syndrome" post="and neurologic toxicity associated with immune effector cellsBiol Blood"/>
 <result pre="release syndrome and neurologic toxicity associated with immune effector cellsBiol" exact="Blood" post="Marrow Transpl2019254625638 116.ParkJHRomeroFATaurYSadelainMBrentjensRJHohlTMSeoSKCytokine release syndrome grade as a predictive"/>
 <result pre="associated with immune effector cellsBiol Blood Marrow Transpl2019254625638 116.ParkJHRomeroFATaurYSadelainMBrentjensRJHohlTMSeoSKCytokine release" exact="syndrome" post="grade as a predictive marker for infections in patients"/>
 <result pre="Transpl2019254625638 116.ParkJHRomeroFATaurYSadelainMBrentjensRJHohlTMSeoSKCytokine release syndrome grade as a predictive marker for" exact="infections" post="in patients with relapsed or refractory B-cell acute lymphoblastic"/>
 <result pre="marker for infections in patients with relapsed or refractory B-cell" exact="acute lymphoblastic leukemia" post="treated with chimeric antigen receptor T cellsClin Infect Dis201867453354029481659"/>
 <result pre="for infections in patients with relapsed or refractory B-cell acute" exact="lymphoblastic leukemia" post="treated with chimeric antigen receptor T cellsClin Infect Dis201867453354029481659"/>
 <result pre="infections in patients with relapsed or refractory B-cell acute lymphoblastic" exact="leukemia" post="treated with chimeric antigen receptor T cellsClin Infect Dis201867453354029481659"/>
 <result pre="119.StockmanLJBellamyRGarnerPSARS: systematic review of treatment effectsPLoS Med200639E34316968120 120.ChenR-cTangX-pTanS-yLiangB-lWanZ-yFangJ-qZhongNTreatment of severe" exact="acute" post="respiratory syndrome with glucosteroids: the Guangzhou experienceChest200612961441145216778260 121.LeeNChanKAHuiDSNgEKWuAChiuRWWongVWChanPKWongKWongEEffects of"/>
 <result pre="systematic review of treatment effectsPLoS Med200639E34316968120 120.ChenR-cTangX-pTanS-yLiangB-lWanZ-yFangJ-qZhongNTreatment of severe acute" exact="respiratory" post="syndrome with glucosteroids: the Guangzhou experienceChest200612961441145216778260 121.LeeNChanKAHuiDSNgEKWuAChiuRWWongVWChanPKWongKWongEEffects of early"/>
 <result pre="review of treatment effectsPLoS Med200639E34316968120 120.ChenR-cTangX-pTanS-yLiangB-lWanZ-yFangJ-qZhongNTreatment of severe acute respiratory" exact="syndrome" post="with glucosteroids: the Guangzhou experienceChest200612961441145216778260 121.LeeNChanKAHuiDSNgEKWuAChiuRWWongVWChanPKWongKWongEEffects of early corticosteroid"/>
 <result pre="early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in" exact="adult" post="patientsJ Clin Virol200431430430915494274 122.AuyeungTWLeeJSLaiWKChoiCHLeeHKLeeJSLiPCLokKHNgYYWongWMThe use of corticosteroid as treatment"/>
 <result pre="Infect20055129810216038758 123.ArabiYMMandourahYAl-HameedFSindiAAAlmekhlafiGAHusseinMAJoseJPintoRAl-OmariAKharabaACorticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndromeAm J Respir Crit Care Med2018197675776729161116 124.WuCChenXCaiYZhouXXuSHuangHet al.Risk factors"/>
 <result pre="J Respir Crit Care Med2018197675776729161116 124.WuCChenXCaiYZhouXXuSHuangHet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="Respir Crit Care Med2018197675776729161116 124.WuCChenXCaiYZhouXXuSHuangHet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="Care Med2018197675776729161116 124.WuCChenXCaiYZhouXXuSHuangHet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med20201807111 125.ShangLZhaoJHuYDuRCaoBOn the"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med20201807111 125.ShangLZhaoJHuYDuRCaoBOn the use of"/>
 <result pre="in the greater Toronto areaJAMA2003289212801280912734147 127.LeeNHuiDWuAChanPCameronPJoyntGMAhujaAYungMYLeungCToKA major outbreak of severe" exact="acute" post="respiratory syndrome in Hong KongN Engl J Med2003348201986199412682352 128.TanELOoiEELinC-YTanHCLingAELimBStantonLWInhibition"/>
 <result pre="the greater Toronto areaJAMA2003289212801280912734147 127.LeeNHuiDWuAChanPCameronPJoyntGMAhujaAYungMYLeungCToKA major outbreak of severe acute" exact="respiratory" post="syndrome in Hong KongN Engl J Med2003348201986199412682352 128.TanELOoiEELinC-YTanHCLingAELimBStantonLWInhibition of"/>
 <result pre="greater Toronto areaJAMA2003289212801280912734147 127.LeeNHuiDWuAChanPCameronPJoyntGMAhujaAYungMYLeungCToKA major outbreak of severe acute respiratory" exact="syndrome" post="in Hong KongN Engl J Med2003348201986199412682352 128.TanELOoiEELinC-YTanHCLingAELimBStantonLWInhibition of SARS"/>
 <result pre="in Hong KongN Engl J Med2003348201986199412682352 128.TanELOoiEELinC-YTanHCLingAELimBStantonLWInhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg Infect Dis200410458115200845"/>
 <result pre="and interferon therapy for critically Ill patients with middle east" exact="respiratory" post="syndrome: a multicenter observational studyClin infect Dis201970918371844 130.Nitric oxide"/>
 <result pre="131.CasadevallAScharffMDReturn to the past: the case for antibody-based therapies in" exact="infectious" post="diseasesClin Infect Dis19952111501617578724 132.CasadevallADadachovaEPirofskiAPassive antibody therapy for infectious diseasesNat"/>
 <result pre="therapies in infectious diseasesClin Infect Dis19952111501617578724 132.CasadevallADadachovaEPirofskiAPassive antibody therapy for" exact="infectious" post="diseasesNat Rev Microbiol20042969570315372080 133.ZhangJSChenJTLiuYXZhangZSGaoHLiuYWangXNingYLiuYFGaoQA serological survey on neutralizing antibody"/>
 <result pre="hypothesis: serum IgG antibody is sufficient to confer protection against" exact="infectious diseases" post="by inactivating the inoculumJ Infect Dis19951716138713987769272 136.CasadevallAPirofskiAAntibody-mediated regulation of"/>
 <result pre="the inflammatory responseTrends Immunol200324947447812967670 137.CasadevallAScharffMDSerum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapyAntimicrob Agents Chemother199438816957985997 138.ParkWHTherapeutic"/>
 <result pre="cases of poliomyelitisJ Am Med Assoc1932991310501053 139.ParkWHFreemanRGThe prophylactic use of" exact="measles" post="convalescent serumJ Am Med Assoc1926878556558 140.GallagherJRUse of convalescent measles"/>
 <result pre="of measles convalescent serumJ Am Med Assoc1926878556558 140.GallagherJRUse of convalescent" exact="measles" post="serum to control measles in a preparatory schoolAm J"/>
 <result pre="Am Med Assoc1926878556558 140.GallagherJRUse of convalescent measles serum to control" exact="measles" post="in a preparatory schoolAm J Public Health Nations Health193525559559818014217"/>
 <result pre="Infect Dis201152444745621248066 145.SahrFAnsumanaRMassaquoiTIdrissBSesayFLaminJBakerSNicolSContonBJohnsonWEvaluation of convalescent whole blood for treating Ebola" exact="Virus Disease" post="in Freetown, Sierra LeoneJ Infect201774330230927867062 146.KraftCSHewlettALKoepsellSWinklerAMKratochvilCJLarsonLVarkeyJBMehtaAKLyonGMIIIFriedman-MoracoRJThe use of TKM-100802"/>
 <result pre="Dis201152444745621248066 145.SahrFAnsumanaRMassaquoiTIdrissBSesayFLaminJBakerSNicolSContonBJohnsonWEvaluation of convalescent whole blood for treating Ebola Virus" exact="Disease" post="in Freetown, Sierra LeoneJ Infect201774330230927867062 146.KraftCSHewlettALKoepsellSWinklerAMKratochvilCJLarsonLVarkeyJBMehtaAKLyonGMIIIFriedman-MoracoRJThe use of TKM-100802"/>
 <result pre="TKM-100802 and convalescent plasma in 2 patients with Ebola virus" exact="disease" post="in the United StatesClin Infect Dis201561449650225904375 147.KongLZhouBSuccessful treatment of"/>
 <result pre="disease in the United StatesClin Infect Dis201561449650225904375 147.KongLZhouBSuccessful treatment of" exact="avian influenza" post="with convalescent plasmaHong Kong Med J200612648917148811 148.ZhouBZhongNGuanYTreatment with convalescent"/>
 <result pre="Engl J Med2007357141450145117914053 149.WuX-XGaoH-NWuH-BPengX-MOuH-LLiL-JSuccessful treatment of avian-origin influenza A (H7N9)" exact="infection" post="using convalescent plasmaInt J Infect Dis2015413526482389 150.ChengYWongRSooYWongWLeeCNgMChanPWongKLeungCChengGUse of convalescent"/>
 <result pre="Microbiol Infect Dis2005241444615616839 151.YehK-MChiuehT-SSiuLLinJ-CChanPKPengM-YWanH-LChenJ-HHuB-SPerngC-LExperience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ"/>
 <result pre="Infect Dis2005241444615616839 151.YehK-MChiuehT-SSiuLLinJ-CChanPKPengM-YWanH-LChenJ-HHuB-SPerngC-LExperience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ Antimicrob"/>
 <result pre="Dis2005241444615616839 151.YehK-MChiuehT-SSiuLLinJ-CChanPKPengM-YWanH-LChenJ-HHuB-SPerngC-LExperience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ Antimicrob Chemother200556591992216183666"/>
 <result pre="Chemother200556591992216183666 152.KoJ-HSeokHChoSYHaYEBaekJYKimSHKimY-JParkJKChungCRKangE-SChallenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experienceAntiviral Ther2018237617622 153.ArabiYMHajeerAHLukeTRaviprakashKBalkhyHJohaniSAl-DawoodAAl-QahtaniSAl-OmariAAl-HameedFFeasibility of"/>
 <result pre="ArabiaEmerg Infect Dis2016229155427532807 154.Van ErpEALuytjesWFerwerdaGVan KasterenPBFc-mediated antibody effector functions during" exact="respiratory" post="syncytial virus infection and diseaseFront Immunol20191054830967872 155.JenksJAGoodwinMLPermarSRThe roles of"/>
 <result pre="Dis2016229155427532807 154.Van ErpEALuytjesWFerwerdaGVan KasterenPBFc-mediated antibody effector functions during respiratory syncytial" exact="virus infection" post="and diseaseFront Immunol20191054830967872 155.JenksJAGoodwinMLPermarSRThe roles of host and viral"/>
 <result pre="154.Van ErpEALuytjesWFerwerdaGVan KasterenPBFc-mediated antibody effector functions during respiratory syncytial virus" exact="infection" post="and diseaseFront Immunol20191054830967872 155.JenksJAGoodwinMLPermarSRThe roles of host and viral"/>
 <result pre="virus infection and diseaseFront Immunol20191054830967872 155.JenksJAGoodwinMLPermarSRThe roles of host and" exact="viral" post="antibody Fc receptors in herpes simplex virus (HSV) and"/>
 <result pre="155.JenksJAGoodwinMLPermarSRThe roles of host and viral antibody Fc receptors in" exact="herpes" post="simplex virus (HSV) and human cytomegalovirus (HCMV) infections and"/>
 <result pre="receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV)" exact="infections" post="and immunityFront Immunol201910211031555298 156.Gunn BM, Yu W-H, Karim MM,"/>
 <result pre="on convalescent plasma therapy. https://www.xinhuanet.com/english/2020-02/28/c_138828177.htm. Retrieved 12 Apr 2020 158.GajicORanaRWintersJLYilmazMMendezJLRickmanOBO'ByrneMMEvensonLKMalinchocMDeGoeySRTransfusion-related" exact="acute" post="lung injury in the critically ill: prospective nested case-control"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysis."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysis. J Infect"/>
 <result pre="systematic review and exploratory meta-analysis. J Infect Dis 211(1):80â€&quot;90 161.CroweJEFirestoneC-YMurphyBRPassively" exact="acquired" post="antibodies suppress humoral but not cell-mediated immunity in mice"/>
 <result pre="but not cell-mediated immunity in mice immunized with live attenuated" exact="respiratory" post="syncytial virus vaccinesJ Immunol200116773910391811564809 162.Drugmaker Takeda is working on"/>
 <result pre="Public Health1918810741744 164.MoYFisherDA review of treatment modalities for Middle East" exact="respiratory" post="syndromeJ Antimicrob Chemother201671123340335027585965 165.ShenCWangZZhaoFYangYLiJYuanJet al.Treatment of 5 critically ill"/>
 <result pre="COVID-19 pneumoniaAging Dis202011221622832257537 169.ForonjyRFDaboAJCumminsNGeraghtyPLeukemia inhibitory factor protects the lung during" exact="respiratory" post="syncytial viral infectionBMC Immunol20141514125277705 170.QuintonLJMizgerdJPHilliardKLJonesMRKwonCYAllenELeukemia inhibitory factor signaling is"/>
 <result pre="Dis202011221622832257537 169.ForonjyRFDaboAJCumminsNGeraghtyPLeukemia inhibitory factor protects the lung during respiratory syncytial" exact="viral" post="infectionBMC Immunol20141514125277705 170.QuintonLJMizgerdJPHilliardKLJonesMRKwonCYAllenELeukemia inhibitory factor signaling is required for"/>
 <result pre="Immunol2012188126300630822581855 171.Metcalfe SM, Strom TB, Williams A, Fahmy TM (2015)" exact="Multiple" post="sclerosis and the LIF/IL-6 axis: use of nanotechnology to"/>
 <result pre="cytokines. V. LPS induces expression of LIF and LIF inhibits" exact="acute" post="inflammation. Am J Physiol Lung Cell Mol Physiol 267(4):L442â€&quot;L446"/>
 <result pre="J Physiol Lung Cell Mol Physiol 267(4):L442â€&quot;L446 174.WangJChenQCorneJZhuZLeeCGBhandariVHomerRJEliasJAPulmonary expression of" exact="leukemia" post="inhibitory factor induces B cell hyperplasia and confers protection"/>
 <result pre="267(4):L442â€&quot;L446 174.WangJChenQCorneJZhuZLeeCGBhandariVHomerRJEliasJAPulmonary expression of leukemia inhibitory factor induces B cell" exact="hyperplasia" post="and confers protection in hyperoxiaJ Biol Chem200327833312263123212782633 175.MetcalfeSMMesenchymal stem"/>
</results>
